(Q50670242)

English

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

scientific article published on 9 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. (English)

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

1 reference

based on heuristic

inferred from title

Anthony V. Moorman

7

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

author name string

Ajay Vora

1

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Nick Goulden

2

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Chris Mitchell

3

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Jeremy Hancock

4

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Rachael Hough

5

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Clare Rowntree

6

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Rachel Wade

8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

publication date

9 June 2014

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Lancet Oncology Commission

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

15

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

809-818

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating childhood acute lymphoblastic leukemia without cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification systems for acute and chronic leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970243-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70243-8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24924991

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50670242&oldid=1417677792"